ACST

Acasti Pharma, Inc.

2.34 USD

Last updated Dec 6, 03:52 UTC

Yesterday HIGH

$2.34

Yesterday LOW

$2.15

52w HIGH

$5.05

52w LOW

$1.72

EPS

-0.43

PE

-5.44

Next Earnings

Feb 13, 2024

Overview News Government Trades

Acasti Pharma, Inc. stock is down -4.88% since 30 days ago. The next earnings date is Feb 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 December’s closed higher than November.

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Laval, Canada

Website

acastipharma.com

Benzinga Newsdesk

Tue Jan 17, 2023

Acasti Pharma Discusses Clinical Study Results For GTX-101 And GTX-102 And Upcoming Phase 3 Study For GTX-104 With The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ:ACST), a late-stage specialty pharma company with drug delivery technologies and drug candidates
Lisa Levin

Fri Jan 6, 2023

Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket

Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products that address larger markets.
Benzinga Newsdesk

Thu Jan 5, 2023

Acasti To Host Conference Call On Tuesday, January 10, 2023 To Discuss Results From Recent Phase 1 PK Studies For GTX-101 And GTX-102 That Met All Outcome Measures

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases,
Bill Haddad

Wed Dec 28, 2022

Acasti Announces Preliminary Topline Results Met All Outcome Measures In Pharmacokinetic Bridging Study For GTX-102, The Company's Drug Candidate For Treatment Of Ataxia Telangiectasia
Lisa Levin

Fri Dec 23, 2022

Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session

Gainers
Lisa Levin

Fri Dec 23, 2022

Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket

Gainers Expion360 Inc. (NASDAQ: XPON) shares rose 152% to $2.47 in pre-market trading. Expion360 been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer available through SUV dealerships nationwide.
Bill Haddad

Thu Dec 22, 2022

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures In Single Dose Pharmacokinetic Study For GTX-101

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST, TSXV:ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases,
Lisa Levin

Tue Dec 20, 2022

Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery.
Benzinga Insights

Mon Dec 19, 2022

Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Benzinga Newsdesk

Mon Dec 19, 2022

EF Hutton Initiates Coverage On Acasti Pharma with Buy Rating, Announces Price Target of $2.5

EF Hutton analyst Constantine Davides initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and announces Price Target of $2.5.